Financial Performance
5Y price score: 15
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 109.8%
US$ Per
Share
By default your notes are visible only to you.
42.2
52-week range
109.5
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
4.9 %
Dividend Yield TTM
-
Market cap $
$ 74,110
Price / Earnings TTM
20.3
Price / Book TTM
3
PEG TTM
1.3
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
(52.6) %
11.3 %
109.8 %
Free cash flow per share growth
17.4 %
206.3 %
830 %
Earnings per share growth
15.1 %
2,489.2 %
1,177.8 %
Founded: 1,979
Employees: 53,000
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 29, 2026)
1) Strategic Overview and Leadership Insights - Boston Scientific reported solid Q2 2026 results, with total organic sales growth of 7%, exceeding the guidance of 5% to 7%. - Adjusted EPS of $0.86 grew 15% YoY, surpassing the guidance range of $0.82 to $0.84. - The company is adjusting its full-year 2026 guidance for organic revenue to 5% to 6% and adjusted EPS to $3.28 to $3.32, reflecting a more conservative outlook due to market pressures. - A restructuring program is underway, aiming for $500 million in run rate savings by the end of 2029 to enhance operational efficiency and support future growth.
2) Financial and Segment Performance - Q2 consolidated revenue reached $5.442 billion, marking a 7.5% reported growth YoY. - Adjusted gross margin improved to 70.3%, while adjusted operating margin was 28.4%, reflecting a 70 basis point increase YoY. - Key growth drivers included: - Neuromodulation: Sales grew 12%. - Interventional Cardiology: Sales grew 15%, driven by strong performance in coronary therapies. - Endoscopy: Sales increased by 7%, with notable contributions from the AXIOS product line.
| Segment | Q2 Growth Rate |
|---|---|
| Neuromodulation | 12% |
| Interventional Cardiology | 15% |
| Endoscopy | 7% |
| WATCHMAN | 4% |
| Electrophysiology | 9% |
3) Challenges and Headwinds - The company faces significant challenges in the WATCHMAN and Electrophysiology (EP) segments, leading to a downward revision in growth expectations. - WATCHMAN's U.S. market growth has slowed due to increased clinical evidence affecting referral patterns, with expected declines in the second half of 2026. - Competitive pressures in the EP market have resulted in share loss, necessitating a more conservative outlook for 2027.
4) Operational and Product Plans - Boston Scientific is focused on executing its restructuring plan while investing in high-growth areas. - Upcoming product launches include the SEISMIQ 4CE Coronary IVL Catheter and potential re-entry into the TAVR market through MiRus. - The company anticipates launching several new products by 2028, which are expected to drive future growth, particularly in the Interventional Cardiology and Vascular segments.
5) Guidance and Outlook - For Q3 2026, Boston Scientific is guiding for organic revenue growth of 3% to 5% and adjusted EPS of $0.80 to $0.82. - The company expects limited EPS growth in 2027, primarily due to continued headwinds in WATCHMAN and EP, with a return to stronger growth anticipated in 2028. - The transcript lacks specific figures for the anticipated impact of the restructuring program on the P&L and detailed timelines for product launches.
Bottom line: Boston Scientific's Q2 2026 results reflect solid performance despite challenges in key segments. The company is taking strategic steps to navigate current market pressures while positioning itself for future growth, particularly through upcoming product launches and operational efficiencies. Shareholders should remain cautious but optimistic about the long-term outlook as the company aims for a return to strong growth in 2028 and beyond.
Annual Reports, Presentations And IR Contacts
Go to the websiteBoston Scientific Corporation — Financial Overview, Stock Price, Market Cap
Boston Scientific Corporation is a company. Founded in 1979. As of August 26, 2026, the company's market capitalization is $74109909600 with a current stock price of $49.86.